Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Lokelma for Maximisation of RAAS Inhibition in CKD Patients With Heart Failure; Randomised.

NCT05004363 is registered in ClinicalTrials.gov with St George's, University of London as lead sponsor.

NCT NCT05004363
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05004363 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Lokelma for Maximisation of RAAS Inhibition in CKD Patients With Heart Failure; Randomised.
Lead sponsor
St George's, University of London
Phase
Phase 3
Overall status
Completed
Start date
January 19, 2022
Completion date
July 1, 2024
Enrollment
112 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ace inhibitor induced hyperkalaemia, chronic kidney diseases, heart failure with reduced ejection fraction, hyperkalemia, mineralocorticoid resistant hyperkalemia